In humans, individuals with GH deficiency and GH resistance demonstrate an increased prevalence of NAFLD compared to controls, with improvement in hepatic lipid, steatohepatitis, and fibrosis following GH replacement. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatotic liver disease.